Journal articles: 'Pharmaceutical microbiology'

1

Sandle, Tim. "Interview: Pharmaceutical microbiology." Pharmaceutical Bioprocessing 2, no. 1 (February 2014): 17–21. http://dx.doi.org/10.4155/pbp.13.64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Brown, Stephen J. "Pharmaceutical Microbiology, 7th edn." Journal of Antimicrobial Chemotherapy 44, no. 1 (July 1999): 139. http://dx.doi.org/10.1093/jac/44.1.139a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Rimbara, Emiko. "Hugo and Russell’s Pharmaceutical Microbiology." Helicobacter 17, no. 3 (April 8, 2012): 240. http://dx.doi.org/10.1111/j.1523-5378.2012.00951.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Surrette, C., B. Scherer, A. Corwin, G. Grossmann, A. M. Kaushik, K. Hsieh, P. Zhang, et al. "Rapid Microbiology Screening in Pharmaceutical Workflows." SLAS TECHNOLOGY: Translating Life Sciences Innovation 23, no. 4 (July 20, 2018): 387–94. http://dx.doi.org/10.1177/2472630318779758.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kurtböke, İpek, and Ian Macreadie. "Industrial microbiology." Microbiology Australia 38, no. 2 (2017): 51. http://dx.doi.org/10.1071/ma17025.

Full text

Abstract:

The exploitation of microorganisms has been part of humankind for millennia. Today this use has increased immensely as we re-purpose microorganisms in many novel ways to facilitate processes in food, pharmaceutical, detergent and mining industries. This issue of Microbiology Australia includes a brief look at the breadth of Industrial Microbiology and what it is offering us now and into the future.

APA, Harvard, Vancouver, ISO, and other styles

6

Shub, T. A., G. Ya Kivman, V. S. Chudaeva, V. G. Maslennikova, and O. N. Al'bitskaya. "Use ofChlorella hydrolysate in culture media and pharmaceutical microbiology." Pharmaceutical Chemistry Journal 28, no. 7 (July 1994): 513–15. http://dx.doi.org/10.1007/bf02219251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Laskaris, Paris, and Amalia D. Karagouni. "Streptomyces, Greek Habitats and Novel Pharmaceuticals: A Promising Challenge." Microbiology Research 12, no. 4 (November 6, 2021): 840–46. http://dx.doi.org/10.3390/microbiolres12040061.

Full text

Abstract:

Bacteria of the genus Streptomyces produce a very large number of secondary metabolites, many of which are of vital importance to modern medicine. There is great interest in the discovery of novel pharmaceutical compounds derived from strepomycetes, since novel antibiotics, anticancer and compounds for treating other conditions are urgently needed. Greece, as proven by recent research, possesses microbial reservoirs with a high diversity of Streptomyces populations, which provide a rich pool of strains with potential pharmaceutical value. This review examines the compounds of pharmaceutical interest that have been derived from Greek Streptomyces isolates. The compounds reported in the literature include antibiotics, antitumor compounds, biofilm inhibitors, antiparasitics, bacterial toxin production inhibitors and antioxidants. The streptomycete biodiversity of Greek environments remains relatively unexamined and is therefore a very promising resource for potential novel pharmaceuticals.

APA, Harvard, Vancouver, ISO, and other styles

8

Morita, Yuji, and Kunihiko Nishino. "Frontier of Pharmaceutical Microbiology: To Combat Multidrug-resistant Bacterial Pathogens." YAKUGAKU ZASSHI 137, no. 4 (April 1, 2017): 371–72. http://dx.doi.org/10.1248/yakushi.16-00235-f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kaur, Navjot, and Vishu Chaudhary. "Biotherapeutics and its applications in Microbiology." Environment Conservation Journal 22, SE (March 8, 2021): 63–78. http://dx.doi.org/10.36953/ecj.2021.se.2207.

Full text

Abstract:

Biotherapeutics is a rapidly growing segment of the entire pharmaceutical industry that constitutes approximately one-quarter of ongoing new drug endorsements. Monoclonal antibodies are a major part of these endorsements every year (mAbs). MAbs' non-clinical pharmacology and toxicology research compare with substance components during progression, since these biotherapeutics are extracted from an organic source, and to inspire a pharmacological reaction, the creature models must also have similar epitopes (focuses) as individuals. Biotherapeutic items (BTPs) are the quickest developing drugs in the pharmaceutical market. Despite their clinical achievement, the immunogenicity of BTPs keeps on being a significant concern. The subcutaneous (SC) course is to cultivate a passion for the organisation of biotherapeutics. Both monoclonal antibodies and various biotherapeutics are discussed. Medicine has been disrupted by biotherapeutic drugs (BPs), altering the way we treat a few processes. Comparative BPs (SBPs) are discussed here, also called biosimilars, including the assembly process and administrative viewpoints used. Monoclonal antibodies can apply synergistic antitumour impacts in blend with other immunomodulatory approaches, for example, chemotherapy, radiotherapy, directed treatment specialists, immunisations, or different immunomodulators. Probiotics have gotten profoundly perceived as enhancements for people and specifically for creatures given their gainful result on wellbeing improvement and prosperity support.

APA, Harvard, Vancouver, ISO, and other styles

10

Lateef, A. "The microbiology of a pharmaceutical effluent and its public health implications." World Journal of Microbiology and Biotechnology 20, no. 2 (March 2004): 167–71. http://dx.doi.org/10.1023/b:wibi.0000021752.29468.4e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Antraygues, Kevin, Nina Compagne, Francesca Ruggieri, Kamel Djaout, Zainab Edoo, Maxime Eveque, Léo Faïon, et al. "On the Hunt for Next-Generation Antimicrobial Agents: An Online Symposium Organized Jointly by the French Society for Medicinal Chemistry (Société de Chimie Thérapeutique) and the French Microbiology Society (Société Française de Microbiologie) on 9–10 December 2021." Pharmaceuticals 15, no. 4 (March 23, 2022): 388. http://dx.doi.org/10.3390/ph15040388.

Full text

Abstract:

The restrictions posed by the COVID-19 pandemic obliged the French Society for Medicinal Chemistry (Société de chimie thérapeutique) and the French Microbiology Society (Société Française de Microbiologie) to organize their joint autumn symposium (entitled “On the hunt for next-generation antimicrobial agents”) online on 9–10 December 2021. The meeting attracted more than 200 researchers from France and abroad with interests in drug discovery, antimicrobial resistance, medicinal chemistry, and related disciplines. This review summarizes the 13 invited keynote lectures. The symposium generated high-level scientific dialogue on the most recent advances in combating antimicrobial resistance. The University of Lille, the Institut Pasteur de Lille, the journal Pharmaceuticals, Oxeltis, and INCATE, sponsored the event.

APA, Harvard, Vancouver, ISO, and other styles

12

Woodward, Janet H. "Microscopy, Microbiology and Regulations of Paper and Paperboard Utilized in Pharmaceutical Packaging." Microscopy and Microanalysis 21, S3 (August 2015): 61–62. http://dx.doi.org/10.1017/s1431927615001105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

A P, Sreekala, Anup B. Thakar, Harisha C. R, and Shukla V. J. "Pharmaceutico-Analytical study of Shadbindu taila." International Journal of Ayurvedic Medicine 12, no. 2 (June 29, 2021): 332–37. http://dx.doi.org/10.47552/ijam.v12i3.1878.

Full text

Abstract:

Introduction: Shadbindu taila is an Ayurvedic herbo-mineral preparation used in a variety of clinical conditions especially in diseases of upper part of body. This taila is described as exceptionally beneficial for improving the strength of hands. Before a human trial it is essential to evaluate the quality and authenticity of the trial drug, Standardization is needed for assuring quality of any drug and it should be started with the identification and authentication of the drug Materials and method: Pharmacognostical evaluation carried out at Pharmacognosy department, ITRA, Jamnagar, pharmaceutical and HPTLC study were done at Pharmaceutical chemistry department, ITRA, Jamnagar. Microbiological evaluation was carried out at department of Microbiology I.T.R.A, Jamnagar. Results: Organoleptic examination: Colour: Greenish Brown, Odour: Aromatic, Taste: Salty, Touch: Viscous, oily. Pharmaceutical evaluation: specific gravity 0.9177, density 0.8753 Refractive Index 1 .4860, Acid Value 4.042, Saponification Value 132.43, Iodine Value 169.33 HPTLC at 254nm (short wave) showed mainly 6 major spot and at 366 nm (long wave) showed 2 major spots. No organisms isolated in aerobic and fungal culture, in microbiology evaluation. Conclusion: The trial drug is authentic and devoid of any adulteration. All quality control parameters were found to be within the permissible pharmacopeial limits and the stability and shelf life of the trial drug also will be more as per the pharmaceutical parameters.

APA, Harvard, Vancouver, ISO, and other styles

14

Lolas, Anastasia. "The role of microbiology in the design and development of pharmaceutical manufacturing processes." Pharmaceutical Bioprocessing 2, no. 2 (April 2014): 125–28. http://dx.doi.org/10.4155/pbp.14.6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Austin, B. "Novel pharmaceutical compounds from marine bacteria." Journal of Applied Bacteriology 67, no. 5 (November 1989): 461–70. http://dx.doi.org/10.1111/j.1365-2672.1989.tb02517.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Elbadawi, Lina, Nadine Shehab, Jennifer N. Lind, Alexander Kallen, Melissa K. Schaefer, and Kiran Perkins. "Investigation of Events Related to Laboratory-Confirmed Contamination of Pharmaceutical Products: Summary of CDC Consultation." Infection Control & Hospital Epidemiology 41, S1 (October 2020): s10—s11. http://dx.doi.org/10.1017/ice.2020.482.

Full text

Abstract:

Background: Contaminated pharmaceutical products pose serious infection risks to patients and can lead to significant morbidity and mortality. Contamination at the point of manufacturing or compounding (intrinsic contamination) has the potential to affect large numbers of patients. Public health plays a critical role in detecting and investigating such events. We identified investigations involving intrinsically contaminated pharmaceuticals to characterize the burden and scope of harm associated with these events. Methods: We reviewed Centers for Disease Control and Prevention records to identify US investigations between January 1, 2009, and December 31, 2018, involving laboratory-confirmed contamination of manufactured medications and pharmacy-compounded preparations (P-CPs), using relevant search terms (eg, “medication contamination”). Laboratory confirmation was defined as identification of a pathogen from a manufactured medication or P-CP. We determined the number and type of patient infections associated with these investigations, the number of states involved, pathogens identified, type of medication (sterile or nonsterile), route of administration, and how the contamination event was first identified. We excluded investigations when the mode of production was unknown. Results: We identified 20 investigations in at least 20 states involving laboratory-confirmed contamination of manufactured medications (n = 12) and P-CPs (n = 8). Patient infections were identified in 16 (80%) investigations (9 involving manufactured medications and 7 involving P-CPs) resulting in at least 1,183 infections and at least 73 deaths. Bloodstream infections were the most common infection type (n = 7, 44%). Waterborne pathogens (eg, Serratia marcescens, Burkholderia cepacia) were cultured from medications in 83% (n = 10) of investigations involving manufactured medications and 75% (n = 6) of investigations involving P-CPs. Contamination of sterile pharmaceutical products occurred in 14 (70%) investigations; 11 (79%) of these involved injectables. Information regarding how contaminated pharmaceuticals were first identified was documented for 18 investigations; most cases (n = 14, 78%) started with investigation of patient infections by facilities, public health, or both, which led to laboratory testing of pharmaceuticals and confirmation of contamination. Conclusions: The events summarized here likely underestimate the frequency of intrinsic contamination of pharmaceutical products in the United States. These events can have devastating consequences that impact patients across the country. Waterborne pathogens appear to be the most frequently identified source of contamination in both manufactured medications and P-CPs.Detection, investigation, control, and prevention of pharmaceutical contamination events benefit from collaboration between state and federal public health authorities; without public health intervention. Such contamination may have gone undetected and could have harmed additional patients.Funding: NoneDisclosures: None

APA, Harvard, Vancouver, ISO, and other styles

17

Klos, Liudmyla. "CONTINUING PROFESSIONAL TRAINING OF PHARMACEUTICAL INDUSTRY PERSONNEL USING REMOTE TECHNOLOGIES." Науковий вісник Інституту професійно-технічної освіти НАПН України Професійна педагогіка, no. 2(19) (November 25, 2019): 86–91. http://dx.doi.org/10.32835/2223-5752.2019.19.86-91.

Full text

Abstract:

Relevance: the need for the development and experimental verification of lifelong learning, namely: mi- crobiology, virology and immunology of future Masters of pharmacy (during studying in higher educational institution and after its graduation, their professional career in the context of society informatization). Aim: to analyze the state of preparation of Masters of pharmacy in the study of microbiology, virology and immunology in the conditions of society informatization. Methods: theoretical (analysis, synthesis, generalization); empirical (expert evaluation and self-assessment methods; questionnaire). Results: the modernization update of the purpose and contents of teaching the future Masters of pharmacy in microbiology, virology and immunology is proposed. An attempt has been made to introduce such a system of training, which would be aimed at the formation of professional knowledge of future Masters of pharmacy, continuous improvement of their professional competences, meaningful practical application of the obtained theoretical knowledge and the acquisition of new knowledge (that appears in the scientific space), the forma- tion of appropriate skills, effective communication formation in the professional pharmaceutical environment through remote technologies. Conclusions: the author has proved that the profession of provisor is inherently a process of constant self- development and self-improvement, with the help of which pharmaceutical activity will be effective. Considering that the pharmaceutical industry has undergone significant changes in comparison with the last century, and requires continuous scientific and educational education, it is concluded that the modern provisor should be able to improve his personal professional qualification at the convenient time for him, remotely, including by online and offline.

APA, Harvard, Vancouver, ISO, and other styles

18

van Bergen, Tamara J. H. M., Ana B. Rios-Miguel, Tom M. Nolte, Ad M. J. Ragas, Rosalie van Zelm, Martien Graumans, Paul T. J. Scheepers, Mike S. M. Jetten, A. Jan Hendriks, and Cornelia U. Welte. "Do initial concentration and activated sludge seasonality affect pharmaceutical biotransformation rate constants?" Applied Microbiology and Biotechnology 105, no. 16-17 (August 2021): 6515–27. http://dx.doi.org/10.1007/s00253-021-11475-9.

Full text

Abstract:

Abstract Pharmaceuticals find their way to the aquatic environment via wastewater treatment plants (WWTPs). Biotransformation plays an important role in mitigating environmental risks; however, a mechanistic understanding of involved processes is limited. The aim of this study was to evaluate potential relationships between first-order biotransformation rate constants (kb) of nine pharmaceuticals and initial concentration of the selected compounds, and sampling season of the used activated sludge inocula. Four-day bottle experiments were performed with activated sludge from WWTP Groesbeek (The Netherlands) of two different seasons, summer and winter, spiked with two environmentally relevant concentrations (3 and 30 nM) of pharmaceuticals. Concentrations of the compounds were measured by LC–MS/MS, microbial community composition was assessed by 16S rRNA gene amplicon sequencing, and kb values were calculated. The biodegradable pharmaceuticals were acetaminophen, metformin, metoprolol, terbutaline, and phenazone (ranked from high to low biotransformation rates). Carbamazepine, diatrizoic acid, diclofenac, and fluoxetine were not converted. Summer and winter inocula did not show significant differences in microbial community composition, but resulted in a slightly different kb for some pharmaceuticals. Likely microbial activity was responsible instead of community composition. In the same inoculum, different kb values were measured, depending on initial concentration. In general, biodegradable compounds had a higher kb when the initial concentration was higher. This demonstrates that Michealis-Menten kinetic theory has shortcomings for some pharmaceuticals at low, environmentally relevant concentrations and that the pharmaceutical concentration should be taken into account when measuring the kb in order to reliably predict the fate of pharmaceuticals in the WWTP. Key points • Biotransformation and sorption of pharmaceuticals were assessed in activated sludge. • Higher initial concentrations resulted in higher biotransformation rate constants for biodegradable pharmaceuticals. • Summer and winter inocula produced slightly different biotransformation rate constants although microbial community composition did not significantly change. Graphical abstract

APA, Harvard, Vancouver, ISO, and other styles

19

Kolář, Milan. "Sepsis from the clinical microbiology point of view." Klinická farmakologie a farmacie 30, no. 3 (December 1, 2016): 29–32. http://dx.doi.org/10.36290/far.2016.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bryukhovetskaya, Natalia, and Liliia Ivanenko. "Intelligent Industries of Ukraine: Major Players and Trends in the Pharmaceutical Industry." Herald of the Economic Sciences of Ukraine, no. 2(39) (2020): 3–8. http://dx.doi.org/10.37405/1729-7206.2020.2(39).3-8.

Full text

Abstract:

The results of a study of the current state and development trends of domestic enterprises-manufacturers of pharmaceutical products and drugs, the relevance of which is due to the need for scientific and methodological support of digital transformation of business models of enterprises in the real sector of the Ukrainian economy, are presented. In the context of aggravated competition, the need to create conditions for the development of the domestic pharmaceutical industry is characterized by specific innovative processes, a complex structure, a large number of high-tech jobs, high investment attractiveness, is an essential condition for improving the quality and competitiveness of pharmaceutical products in the domestic market, intellectualization of enterprises. The purpose of the article is to establish trends in the development of pharmaceutical enterprises to further determine the methods of functioning and development of intellectualized industries in Ukraine. It has been determined that during crisis periods, the dynamics of industrial production of enterprises with a high level of intellectualization is characterized by relative stability against the background of a general decline in business activity. The influence of changes in the direction of global trends in the development of the world pharmaceutical market on the domestic pharmaceutical industry has been established: a double-digit growth trend in sales of prescription drugs (double-digit growth) persists due to the implementation of the reimbursement mechanism, as well as an increase in hospital purchases. Maintaining the market growth trend and the corresponding prolongation of state programs such as “Affordable Medicines” contributes to an increase in demand in the domestic market, which can become a stimulating factor for the further development of domestic pharmaceutical manufacturers – the growth of their business, innovation and investment activity. The analysis indicates a high level of resilience of the pharmaceutical industry and the enterprises that form it to crisis influences, optimistic expectations regarding further moderate growth in the industry, potential growth in the investment attractiveness of domestic enterprises and their high adaptability to transformations of the business model towards its further digitalization and intellectualization.

APA, Harvard, Vancouver, ISO, and other styles

21

Forgoza, Elaine, and Jorge Magalhães. "IMPROVEMENT IN THE MANAGEMENT OF PROCESSES FOR THE ACQUISITION AND STANDARDIZATION OF PHARMACEUTICAL INGREDIENTS IN A SCHOOL LABORATORY." Problems of Management in the 21st Century 17, no. 1 (December 20, 2022): 25–35. http://dx.doi.org/10.33225/pmc/22.17.25.

Full text

Abstract:

The pharmaceutical industry is a dynamic sector in terms of innovation and management. The sector generates around US$ 1.5 trillion a year. In this sense, continuous improvement actions in the management of its processes are constantly present. However, the training of its professionals permeates strict knowledge in the field of quality, pharmaceutical legislation, and public health since education generates knowledge and provides innovation. Therefore, studying quality management, processes and innovation for the education sector and industry are fundamental for companies and organizations in the health area in the 21st century to improve the management of the acquisition of inputs. The results point to gains for the implementation of the Guideline for Standardization and Acquisition of pharmaceutical ingredients in their respective processes. Keywords: knowledge management, process control, quality management, pharmaceutical laboratory

APA, Harvard, Vancouver, ISO, and other styles

22

Silveira, Rosimar L., Simone S. Andrade, Cleber A. Schmidt, Renata G. Casali, and Sérgio L. Dalmora. "Comparative evaluation of pyrogens tests in pharmaceutical products." Brazilian Journal of Microbiology 35, no. 1-2 (June 2004): 48–53. http://dx.doi.org/10.1590/s1517-83822004000100007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Chanalia, Preeti, Dimpi Gandhi, Drukshakshi Jodha, and Jasbir Singh. "Applications of microbial proteases in pharmaceutical industry." Reviews in Medical Microbiology 22, no. 4 (October 2011): 96–101. http://dx.doi.org/10.1097/mrm.0b013e3283494749.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Kocherovets, V. I., and S. G. Mardanly. "Nifuroxazide Pharmaceutical Preparations in the Russian Federation. Publication One: Nomenclature, Chemical and Pharmaceutical Characteristics of the Preparations’ Composition." Antibiotics and Chemotherapy 66, no. 7-8 (October 21, 2021): 90–98. http://dx.doi.org/10.37489/0235-2990-2021-66-7-8-90-98.

Full text

Abstract:

One of the most used antimicrobial nitrofurans in Russian medical practice is nifuroxazide, which is distinguished by high therapeutic eﬃcacy, drug safety, as well as economic availability in the treatment of acute bacterial diarrhea without deterioration of the general condition, fever, and intoxication. In the Russian Federation (RF), nifuroxazide preparations in general circulation are supplied by 19 domestic and foreign pharmaceutical organizations. The aim of this study was to analyze the nomenclature, as well as chemical and pharmaceutical characteristics of excipients (EXs) in the composition of nifuroxazide preparations, which received state registration in the RF. A comparative study of the chemical and pharmaceutical characteristics of EXs of 42 nifuroxazide preparations in the form of capsules, tablets, and suspension for oral administration was carried out. The pharmaco-economic status is noted and the demand prospects for all forms of nifuroxazide preparations in the RF are outlined. Quantitative and qualitative diﬀerences in the composition of the EXs of a number of nifuroxazide preparations in the form of capsules and suspensions has been shown.

APA, Harvard, Vancouver, ISO, and other styles

25

Gunaseelan, R., and T. Viswanathan. "Identification and Molecular Characterization of Microbial Isolates from Purified Water Used in Pharmaceutical Industry." Journal of Pure and Applied Microbiology 13, no. 3 (September 30, 2019): 1815–21. http://dx.doi.org/10.22207/jpam.13.3.58.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

McGonigle, Eugene. "Pharmaceutical Intermediate Supply." Nature Biotechnology 4, no. 7 (July 1986): 661. http://dx.doi.org/10.1038/nbt0786-661a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hodgson, John. "Reconstructing pharmaceutical instinct." Nature Biotechnology 20, no. 12 (December 2002): 1199–203. http://dx.doi.org/10.1038/nbt1202-1199.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Spalding, B. J. "Trashing Pharmaceutical Firms." Nature Biotechnology 10, no. 12 (December 1992): 1516–17. http://dx.doi.org/10.1038/nbt1292-1516.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

CLAERBOUT, MARK EUGENE. "APPLICATIONS FOR BACTERIAL MEMBRANE FRACTIONS IN STERILE PHARMACEUTICAL QUALITY CONTROL." Journal of Rapid Methods and Automation in Microbiology 5, no. 1 (January 1997): 21–28. http://dx.doi.org/10.1111/j.1745-4581.1997.tb00145.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

JIMENEZ, LUIS, RAYMOND IGNAR, ROBERT D'AIELLO, and PAUL GRECH. "USE OF PCR ANALYSIS FOR STERILITY TESTING IN PHARMACEUTICAL ENVIRONMENTS." Journal of Rapid Methods and Automation in Microbiology 8, no. 1 (April 2000): 11–20. http://dx.doi.org/10.1111/j.1745-4581.2000.tb00343.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

FARAJNIA, S., M. HASSAN, S. HALLAJ NEZHADI, L. MOHAMMADNEJAD, M. MILANI, and F. LOTFIPOUR. "DETERMINATION OF INDICATOR BACTERIA IN PHARMACEUTICAL SAMPLES BY MULTIPLEX PCR." Journal of Rapid Methods & Automation in Microbiology 17, no. 3 (September 2009): 328–38. http://dx.doi.org/10.1111/j.1745-4581.2009.00154.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Sousa Silva, Maria Tereza de, Edison Nunes da Silva Junior, Jorge Magalhães, and Vanessa da Silveira dos Santos Pacheco. "THE MANAGEMENT OF PROCESS LEAD TIME IN THE RELEASE OF STERILE PHARMACEUTICAL BATCHES: A CASE STUDY OF OPTIMIZATION IN AN OFFICIAL BRAZILIAN PHARMACEUTICAL LABORATORY." Problems of Management in the 21st Century 16, no. 1 (June 20, 2021): 42–51. http://dx.doi.org/10.33225/pmc/21.16.42.

Full text

Abstract:

Medicines must comply with quality, safety, and efficacy pillars. Nowadays, organizations seek to incorporate new management models encouraged by quality program following the world trend regarding the technological revolution. The present research aims to improve the sterile pharmaceutical product batches release process, using the Failure Mode Effects Analysis (FMEA) method. This study addresses the gap in literature on quality risk management during batch release. The methodology uses a form adapted to the process in order to systematize the information, improving its comparison and analysis, thus estimating, the identification of potential failure modes and their effects on their performance. Made it possible to assign values for the severity, occurrence, and failure modes detection, to then determine the risk level and the priority of risk level. The results obtained showed the mitigation and elimination of failures in the process, as well as opportunities for improvement and causes of failures identification, improvement in the process performance indicators, greater reliability, and reduction in batch release time. Keywords: good manufacturing practices pharmaceutical industry, risk management, risk management tools

APA, Harvard, Vancouver, ISO, and other styles

33

Yuen, Chun-Ting, Yong Zhou, Qing-Zhou Wang, Ji-Feng Hou, Adrian Bristow, and Jun-Zhi Wang. "Glycan analysis of glycoprotein pharmaceuticals: Evaluation of analytical approaches to Z number determination in pharmaceutical erythropoietin products." Biologicals 39, no. 6 (November 2011): 396–403. http://dx.doi.org/10.1016/j.biologicals.2011.08.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

de Magalhães, Jorge Lima, Luc Quoniam, and Núbia Boechat. "PHARMACEUTICAL MARKET AND OPPORTUNITY IN THE 21ST CENTURY FOR GENERIC DRUGS: A BRAZILIAN CASE STUDY OF OLANZAPINE." Problems of Management in the 21st Century 6, no. 1 (April 5, 2013): 31–39. http://dx.doi.org/10.33225/pmc/13.06.31.

Full text

Abstract:

This paper aimed to identify and analyse the evolution of the generic pharmaceutical market in Brazil, specifically olanzapine drugs. For this purpose, it has been demonstrated trends through access free tools. By bibliographical survey in indexed databases as well as official data in Brazil for generic drugs and public policy, it was analyzed and performed a case study . In 2012, global pharmaceutical industry surpassed US$ 950 billion in sales with trend to reach US$ 1,2 trillion by 2016. In Brazil market has grown in its global ranking, jumped from 10th place to 7th place in five years and projection it’ll stay Top five by 2015. Brazil has significant presence in pharmerging markets by increasing US$ 10 billion/year. Generics segment accounts approximately to 20% of the total market. 2003-2011 registered a growth of 42.3%. Patents expiration in the neuroleptics area becomes more promising like a market of olanzapine in the last eight years is around US$ 120 million. After the end of the olanzapine patent (2011) sales increased 270% which demonstrate potential Brazilian market in this new century. Management problems for developing nations and undeveloped such as network management and patents analysis for health care might reveal great opportunities for investors, e.g., creation of the Big Brazilian biotechnology pharmaceutical industry. Keywords: competitive intelligence, pharmaceutical trends, technological and innovation management.

APA, Harvard, Vancouver, ISO, and other styles

35

Mukimin, Aris, and Hanny Vistanty. "Hybrid advanced oxidation process (HAOP) as an effective pharmaceutical wastewater treatment." E3S Web of Conferences 125 (2019): 03007. http://dx.doi.org/10.1051/e3sconf/201912503007.

Full text

Abstract:

Pharmaceutical wastewater may contain bio-refractory and toxic compounds that cannot be treated by microbiology methods. In addition to low efficiency, bacteria will be collapsed and biomass wash-out will occur and be detected as TSS. Hybrid advanced oxidation process (HAOP), based on the electrochemical method, is highly potential for degradation of stable compounds. Cylinder cathode made of carbon cloth was paired with Ti/PtIr anode and inter-electrode distance of 1-3 cm. The cell was equipped with a magnetic stirrer to improve the oxidation-reduction on the surface of the electrode thus enhancing contact between pollutant and generated oxidator. Applied at electrolyte of 4000 mg/L, ferrous sulfate of 0.2 mM, and pH value of 2.5, HAOP showed an excellent performance and reached 60%, 90%, and 94% of COD reduction after 3, 6, and 9 hrs.

APA, Harvard, Vancouver, ISO, and other styles

36

Akande-Sholabi, W., and A. A. Akinbitan. "Assessment of attitude, practice and barriers to pharmaceutical care among community pharmacists in Ibadan." Nigerian Journal of Pharmaceutical Research 18, no. 1 (July 27, 2022): 75–84. http://dx.doi.org/10.4314/njpr.v18i1.8.

Full text

Abstract:

Background: Pharmaceutical care (PC) is a professional responsibility of a pharmacist that involves medication management with the overall goal of improving the quality of life of patient.Objectives: To evaluate the attitude, practice, and barriers to PC among community pharmacists in Ibadan.Method: A cross-sectional survey was conducted among community pharmacists between May and July 2021, with the aid of a self-administered questionnaires, information on socio-demographic characteristics, practice, attitudes, and barriers to PC was obtained. A consecutive sampling technique was used for participants’ enrolment. Participating pharmacists must have had a minimum of one-year practice experience in a community pharmacy. Pharmacy students, interns, non-pharmacist attendants, and community pharmacists who were absent from their pharmacies during the study were excluded. Data were summarized with descriptive statistics.Results: Over 12 weeks, 120 survey were collected (90.9% response rate). About (115; 95.8%) of respondents had good practice of PC and reported that pharmaceutical care is a timely innovation to pharmacy practice. However, only (62; 52.0%) had positive attitude and (117; 97.5%) believed more pharmaceutical care could be provided. Regarding their practice, most respondents (118; 98.3%) stated pharmaceutical care involves monitoring improvement in patient response to treatment and adherence to treatment regime and counselling patients with drug therapy problems. The top detected barriers for PC provision included insufficient time (71; 59.2%), and inadequate collaboration with other healthcare professionals (56; 46.7%).Conclusion: Community pharmacists in Ibadan demonstrated good practice and positive attitudes towards PC provision. However, further work should emphasise on improving PC understanding, better collaboration among other healthcare professionals and overcoming system-related barriers.

APA, Harvard, Vancouver, ISO, and other styles

37

Dahiya, Divakar, and Poonam Singh Nigam. "An overview of three biocatalysts of pharmaceutical importance synthesized by microbial cultures." AIMS Microbiology 7, no. 2 (2021): 124–37. http://dx.doi.org/10.3934/microbiol.2021009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

de M Ribeiro, Lígia N., and Belchiolina B. Fonseca. "The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic." Future Microbiology 15, no. 16 (October 2020): 1571–82. http://dx.doi.org/10.2217/fmb-2020-0118.

Full text

Abstract:

There is no effective therapy against COVID-19 available so far. In the last months, different drugs have been tested as potential treatments for COVID-19, exhibiting high toxicity and low efficacy. Therefore, nanotechnology can be applied to improve the therapeutic action and minimize the toxicity of loaded drugs. In this review, we summarized the drugs tested as COVID-19 treatment and the advantages of antiviral nanostructured drug-delivery systems. Such systems have demonstrated low in vitro toxicity with better in vitro antiviral activity than free drugs. We believe that this approach should inspire novel nanostructured drug-delivery systems developments to find efficient COVID-19 treatments. Here, we discuss the remaining challenges for such promising nanosystems to be approved for clinical use.

APA, Harvard, Vancouver, ISO, and other styles

39

Lawrence, John R., George D. W. Swerhone, Leonard I. Wassenaar, and Thomas R. Neu. "Effects of selected pharmaceuticals on riverine biofilm communities." Canadian Journal of Microbiology 51, no. 8 (August 1, 2005): 655–69. http://dx.doi.org/10.1139/w05-047.

Full text

Abstract:

Although pharmaceutical and therapeutic products are widely found in the natural environment, there is limited understanding of their ecological effects. Here we used rotating annular bioreactors to assess the impact of 10 µg·L–1of the selected pharmaceuticals ibuprofen, carbamazepine, furosemide, and caffeine on riverine biofilms. After 8 weeks of development, community structure was assessed using in situ microscopic analyses, fluor-conjugated lectin binding, standard plate counts, fluorescent in situ hybridization, carbon utilization spectra, and stable carbon isotope analyses. The biofilm communities varied markedly in architecture although only caffeine treated biofilms were significantly thicker. Cyanobacteria were suppressed by all 4 compounds, whereas the nitrogen containing caffeine, furosemide, and carbamazepine increased algal biomass. Ibuprofen and carbamazepine reduced bacterial biomass, while caffeine and furosemide increased it. Exopolymer content and composition of the biofilms was also influenced. Significant positive and negative effects were observed in carbon utilization spectra. In situ hybridization analyses indicated all treatments significantly decreased the gamma-proteobacterial populations and increased beta-proteobacteria. Ibuprofen in particular increased the alpha-proteobacteria, beta-proteobacteria, cytophaga-flavobacteria, and SRB385 probe positive populations. Caffeine and carbamazepine additions resulted in significant increases in the high GC354c and low GC69a probe positive cells. Live–dead analyses of the biofilms indicated that all treatments influenced the ratio of live-to-dead cells with controls having a ratio of 2.4, carbamazepine and ibuprofen being 3.2 and 3.5, respectively, and furosemide and caffeine being 1.9 and 1.7, respectively. Stable isotope analyses of the biofilms indicated δ13C values shifted to more negative values relative to control biofilms. This shift may be consistent with proportional loss of cyanobacteria and relative increase in algal biomass rather than incorporation of pharmaceutical carbon into microbial biofilm. Thus, at 10 ug·L–1levels pharmaceuticals exhibit both nutrient-like and toxic effects on riverine microbial communities.Key words: carbamazepine, ibuprofen, furosemide, caffeine, laser microscopy, digital imaging, in situ hybridization, stable isotopes.

APA, Harvard, Vancouver, ISO, and other styles

40

Canganella, F., S. Paganini, M. Ovidi, A. M. Vettraino, L. Bevilacqua, S. Massa, and L. D. Trovatelli. "A microbiological investigation on probiotic pharmaceutical products used for human health." Microbiological Research 152, no. 2 (July 1997): 171–79. http://dx.doi.org/10.1016/s0944-5013(97)80009-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Urakov, A. L. "Nikolau Syndrome: Necrotic Activity of Drugs and Ways to Prevent Post-Injection Abscesses (In memory of Professor László A Gömze)." Creative surgery and oncology 12, no. 2 (July 16, 2022): 159–63. http://dx.doi.org/10.24060/2076-3093-2022-12-2-159-163.

Full text

Abstract:

Post-injection abscess, which is the sad finale of Nicolau syndrome, continues to attract the attention of researchers due to the need to clarify the causes of this iatrogenic disease in order to develop effective measures for its prevention. For many years, researchers from all over the world have tried from different perspectives to explain the mechanism of the drugs effect that causes post-injection pain syndrome, infiltration, inflammation, erimatous skin damage, necrosis and abscess (Nicolau syndrome), but to no avail. This has been done only in recent years. There are findings in Russia that show that drugs considered to be of high quality today, in some cases, in addition to specific pharmacological activity, may have necrotic activity of a non-specific nature of action. The findings showed that according to the established pharmaceutical practice and in full compliance with the pharmacopoeia requirements for the quality of medicines, pharmaceutical products produced by different pharmaceutical companies, as well as those included in different series of the same pharmaceutical company, may have different compositions (formulations), contain different ingredients, therefore they may have different physico-chemical properties. In this regard, drugs of different serial numbers and/or different manufacturers, which are considered high-quality today, can be hypertonic solutions, have acidifying or alkalizing activity, have alcohols, aldehydes and heavy metal salts in denaturing concentrations. This is the reason that in some cases drugs have necrotic (cauterizing) activity. In this regard, to prevent Nicolau syndrome, it is proposed to reduce the physico-chemical aggressiveness of drugs. Today, this can be done successfully by diluting them with water for injection 2 to 8 times before injection.

APA, Harvard, Vancouver, ISO, and other styles

42

Punzo, Christine, and John Hodgson. "Scios Buys Nova Pharmaceutical." Nature Biotechnology 10, no. 6 (June 1992): 609–15. http://dx.doi.org/10.1038/nbt0692-609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Britz, Margaret. "A tribute to Professor Arnold L Demain – a lifetime in industrial microbiology." Microbiology Australia 31, no. 2 (2010): 97. http://dx.doi.org/10.1071/ma10097.

Full text

Abstract:

Professor Arnold (Arny) Lester Demain is one of the few scientists who have witnessed the progress of biotechnology in a career that has spanned almost 60 years. He is one of the world?s leading industrial microbiologists who has pioneered discovery in genetic and nutritional regulation of biosynthetic pathways leading to overproduction of a suite of primary and secondary metabolites, and their subsequent scale-up in manufacturing processes. These metabolites have huge economic value due to their application in the food, pharmaceutical and agricultural sectors. In this article, Arny?s story is summarised and put in context of the changing face of biotechnology in the various ?golden ages? of biotechnology. A former Rubbo Orator in 1979, Arny will be visiting Australia again in 2010 to present the closing plenary address at the Genetics of Industrial Microorganisms Symposium (GIMS) in Melbourne, a role he played before at the first GIMS in 1970.

APA, Harvard, Vancouver, ISO, and other styles

44

Boghigian, Brett A., Gargi Seth, Robert Kiss, and Blaine A. Pfeifer. "Metabolic flux analysis and pharmaceutical production." Metabolic Engineering 12, no. 2 (March 2010): 81–95. http://dx.doi.org/10.1016/j.ymben.2009.10.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Durrant, C. "The responsibility of the pharmaceutical industry." Clinical Microbiology and Infection 7, s6 (December 2001): 2–4. http://dx.doi.org/10.1046/j.1469-0691.7.s6.1.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Alurappa, Ramesha, and Srinivas Chowdappa. "Antimicrobial Activity and Phytochemical Analysis of Endophytic Fungal Extracts Isolated from Ethno-Pharmaceutical Plant Rauwolfia tetraphylla L." Journal of Pure and Applied Microbiology 12, no. 1 (March 30, 2018): 317–32. http://dx.doi.org/10.22207/jpam.12.1.38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Daddy Gaoh, Soumana, Ohgew Kweon, Yong-Jin Lee, David Hussong, Bernard Marasa, and Youngbeom Ahn. "A Propidium Monoazide (PMAxx)-Droplet Digital PCR (ddPCR) for the Detection of Viable Burkholderia cepacia Complex in Nuclease-Free Water and Antiseptics." Microorganisms 10, no. 5 (April 30, 2022): 943. http://dx.doi.org/10.3390/microorganisms10050943.

Full text

Abstract:

Pharmaceutical products contaminated with Burkholderia cepacia complex (BCC) strains constitute a serious health issue for susceptible individuals. New detection methods to distinguish DNA from viable cells are required to ensure pharmaceutical product quality and safety. In this study, we have assessed a droplet digital PCR (ddPCR) with a variant propidium monoazide (PMAxx) for selective detection of live/dead BCC cells in autoclaved nuclease-free water after 365 days, in 0.001% chlorhexidine gluconate (CHX), and in 0.005% benzalkonium chloride (BZK) solutions after 184 days. Using 10 μM PMAxx and 5 min light exposure, a proportion of dead BCC was quantified by ddPCR. The detection limit of culture-based method was 104 CFU/mL, equivalent to 9.7 pg/μL for B. cenocepacia J2315, while that of ddPCR was 9.7 fg/μL. The true positive rate from nuclease-free water and CHX using PMAxx-ddPCR assay was 60.0% and 38.3%, respectively, compared to 85.0% and 74.6% without PMAxx (p < 0.05), respectively. However, in BZK-treated cells, no difference in the detection rate was observed between the ddPCR assay on samples treated with PMAxx (67.1%) and without PMAxx (63.3%). This study shows that the PMAxx-ddPCR assay provides a better tool for selective detection of live BCC cells in non-sterile pharmaceutical products.

APA, Harvard, Vancouver, ISO, and other styles

48

Basaran, P., and R. M. Demirbas. "Spectroscopic detection of pharmaceutical compounds from an aflatoxigenic strain of Aspergillus parasiticus." Microbiological Research 165, no. 6 (August 2010): 516–22. http://dx.doi.org/10.1016/j.micres.2009.09.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lynas, Kathie. "Sorting through the Flu Confusion: An Interview with Dr. Donald Low." Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 142, no. 6 (September 2009): 268–69. http://dx.doi.org/10.3821/1913-701x-142.6.268.

Full text

Abstract:

Canadians have been flooded with information about H1N1 influenza, much of it seemingly inconsistent and conflicting. There are signs that the public is responding to all the news about the risks and the remedies with a degree of apathy—with polls showing only 1 in 3 planning to get the H1N1 vaccine. CPJ spoke to Dr. Donald Low, Chief of Microbiology at Mount Sinai Hospital in Toronto, about the causes and the impact of the often confusing barrage of flu information.

APA, Harvard, Vancouver, ISO, and other styles

50

Chu, Weihua. "Exploration of Project and Module-based Teaching Method in Pharmaceutical Microbiology Laboratory Courses for Undergraduate Pharmacy Students." Indian Journal of Pharmaceutical Education and Research 57, no. 1 (January 9, 2023): 28–32. http://dx.doi.org/10.5530/001954641319.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Pharmaceutical microbiology'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles